Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shangke Jiegu Pian
- Development stage
- Phase 4
- Lead developer
- Merro Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Shangke Jiegu Pian is a traditional Chinese medicine (TCM) tablet developed and manufactured by Merro Pharmaceutical. It is composed of twelve ingredients, including Semen Strychni, cinnabar, Carthami flos, Eupolyphaga seu Steleophaga, myrrh, and Notoginseng radix et rhizoma. The formulation is indicated for treating bone fractures, joint injuries, lumbar sprains, and soft tissue trauma. It functions by promoting blood circulation, dispersing blood stasis, reducing swelling, and relieving pain. It is officially recorded in the Chinese Pharmacopoeia and is typically administered orally following fracture reduction to support the healing process.
- Brand names
- SHANGKEJIEGUPIANShangke Jiegu Pian
- Other names
- Shangke Jiegupian上客洁骨片
02
Targets
COX
Beyond the preview
Go deeper on Shangke Jiegu Pian.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shangke Jiegu Pian.